Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial.

Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, Sousa E, Stoll HP; REALITY Trial Investigators.

JAMA. 2006 Feb 22;295(8):895-904.

PMID:
16493102
2.

The paclitaxel (TAXUS)-eluting stent: a review of its use in the management of de novo coronary artery lesions.

Waugh J, Wagstaff AJ.

Am J Cardiovasc Drugs. 2004;4(4):257-68. Review.

PMID:
15285700
3.

Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis.

Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Jüni P.

Lancet. 2007 Sep 15;370(9591):937-48. Review.

PMID:
17869634
4.

Efficacy and safety of sirolimus-eluting stents versus bare-metal stents in coronary artery disease patients with diabetes: a meta-analysis.

Qiao Y, Bian Y, Yan X, Liu Z, Chen Y.

Cardiovasc J Afr. 2013 Aug;24(7):274-9. doi: 10.5830/CVJA-2013-062. Review.

5.

Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis.

Siontis GC, Stefanini GG, Mavridis D, Siontis KC, Alfonso F, Pérez-Vizcayno MJ, Byrne RA, Kastrati A, Meier B, Salanti G, Jüni P, Windecker S.

Lancet. 2015 Aug 15;386(9994):655-64. doi: 10.1016/S0140-6736(15)60657-2. Review.

PMID:
26334160
6.

Meta-analysis of randomized trials comparing the effectiveness of different strategies for the treatment of drug-eluting stent restenosis.

Piccolo R, Galasso G, Piscione F, Esposito G, Trimarco B, Dangas GD, Mehran R.

Am J Cardiol. 2014 Nov 1;114(9):1339-46. doi: 10.1016/j.amjcard.2014.07.069. Epub 2014 Aug 12. Review.

PMID:
25242363
7.

Does endovascular treatment of infra-inguinal arterial disease with drug-eluting stents offer better results than angioplasty with or without bare metal stents?

Antoniou GA, Georgakarakos EI, Antoniou SA, Georgiadis GS.

Interact Cardiovasc Thorac Surg. 2014 Aug;19(2):282-5. doi: 10.1093/icvts/ivu093. Epub 2014 Apr 11. Review.

9.

Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes.

Greenhalgh J, Hockenhull J, Rao N, Dundar Y, Dickson RC, Bagust A.

Cochrane Database Syst Rev. 2010 May 12;(5):CD004587. doi: 10.1002/14651858.CD004587.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;10:CD004587.

PMID:
20464732
10.

Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients.

Giacoppo D, Gargiulo G, Aruta P, Capranzano P, Tamburino C, Capodanno D.

BMJ. 2015 Nov 4;351:h5392. doi: 10.1136/bmj.h5392. Review. Erratum in: BMJ. 2015;351:h6364.

11.

[Drug-eluting stents: do they keep their promises?].

Nordmann A.

Praxis (Bern 1994). 2006 Apr 12;95(15):581-3. Review. German. No abstract available.

PMID:
16640178
12.

[Percutaneous coronary angioplasty in diabetic patients: new prospects with drug-eluting stents].

Warzee F, Legrand V, Scheen AJ.

Rev Med Liege. 2004 Dec;59(12):711-6. Review. French.

PMID:
15658058
13.

Differences in drug-eluting stents used in coronary artery disease.

Synetos A, Toutouzas K, Karanasos A, Stathogiannis K, Triantafyllou G, Tsiamis E, Lerakis S, Stefanadis C.

Am J Med Sci. 2011 Nov;342(5):402-8. doi: 10.1097/MAJ.0b013e3182123938. Review.

PMID:
21629039
14.

Paclitaxel Drug-Eluting Stents in Peripheral Arterial Disease: A Health Technology Assessment.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2015 Nov 1;15(20):1-62. eCollection 2015. Review.

15.

Drug-eluting stents in vascular intervention.

Fattori R, Piva T.

Lancet. 2003 Jan 18;361(9353):247-9. Review.

PMID:
12547552
16.

Pharmacological inhibition of coronary restenosis: systemic and local approaches.

Guerra E, Byrne RA, Kastrati A.

Expert Opin Pharmacother. 2014 Oct;15(15):2155-71. doi: 10.1517/14656566.2014.948844. Epub 2014 Aug 22. Review.

PMID:
25145263
17.

The relationship between late lumen loss and restenosis among various drug-eluting stents: a systematic review and meta-regression analysis of randomized clinical trials.

Brener SJ, Prasad AJ, Khan Z, Sacchi TJ.

Atherosclerosis. 2011 Jan;214(1):158-62. doi: 10.1016/j.atherosclerosis.2010.10.046. Epub 2010 Nov 16. Review.

PMID:
21122853
18.

Role of adjunct pharmacologic therapy in the era of drug-eluting stents.

Douglas JS Jr.

Atheroscler Suppl. 2005 Dec 15;6(4):47-52. Epub 2005 Nov 4. Review.

PMID:
16275124
19.

Impact of metabolic syndrome on re-stenosis development: role of drug-eluting stents.

Goyal SN, Bharti S, Krishnamurthy B, Agrawal Y, Ojha SK, Arya DS.

Diab Vasc Dis Res. 2012 Jul;9(3):177-88. doi: 10.1177/1479164111430336. Epub 2012 Jan 4. Review.

PMID:
22219135
20.

Body Mass Index and Repeat Revascularization After Percutaneous Coronary Intervention: A Meta-analysis.

Wang ZJ, Gao F, Cheng WJ, Yang Q, Zhou YJ.

Can J Cardiol. 2015 Jun;31(6):800-8. doi: 10.1016/j.cjca.2015.01.031. Epub 2015 Jan 30. Review.

PMID:
25921864
Items per page

Supplemental Content

Write to the Help Desk